Who is sponsoring NCT05373030?

NCT05373030 is sponsored by Zhejiang Provincial Center for Disease Control and Prevention.

What drugs are being tested in NCT05373030?

Interventions in NCT05373030: Recombinant adenovirus type-5-vectored COVID-19 vaccine.

Is NCT05373030 still recruiting?

NCT05373030 is currently status unknown. Last updated 13 May 2022.

Last reviewed 2022-05-13 · How we verify

NCT05373030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine

Status unknown Phase 4 Last updated 13 May 2022

What this trial tests

Phase 4 trial testing Recombinant adenovirus type-5-vectored COVID-19 vaccine in Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization in 200 participants. Status unknown.

Timeline

14 May 2022

Primary endpoint
31 December 2022

30 June 2023

Quick facts

Lead sponsor	Zhejiang Provincial Center for Disease Control and Prevention
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	200
Start date	14 May 2022
Primary completion	31 December 2022
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

Recombinant adenovirus type-5-vectored COVID-19 vaccine — full drug profile →

Conditions studied

Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization — all drugs for Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization →

Sponsor

Zhejiang Provincial Center for Disease Control and Prevention — full company profile →

Who can join

Adults 18 to 80, any sex, with Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 is a novel coronavirus infection caused by respiratory droplets and contact transmission. With the spread of the epidemic, it has become a serious threat to global public health. China has launched a full range of vaccination including the third dose of homologous and sequential booster immunization. To further improve COVID-19 vaccine immunization strategy, we start the clinic research about sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine in Zhejiang province.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.
Zhang H, Xu N, Xu Y, Qin P, et al · · 2023 · cited 14× · PMID 37553338 · DOI 10.1038/s41467-023-40489-2
Current clinical status of new COVID-19 vaccines and immunotherapy.
Nagpal D, Nagpal S, Kaushik D, Kathuria H. · · 2022 · cited 6× · PMID 36063274 · DOI 10.1007/s11356-022-22661-1
<i>In vivo</i> gene therapy: A strategy for mutations, degenerations, and tumors.
Wang T, Yu M, Liu P, Song Z, et al · · 2026 · PMID 41141388 · DOI 10.1016/j.gendis.2025.101808

Verify or expand the search:

Other Zhejiang Provincial Center for Disease Control and Prevention trials

Trials by the same sponsor.

NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
NCT05279248 — The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine · Phase 4 · unknown
NCT04817917 — Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Differen · Phase 4 · unknown
NCT04576910 — Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China · Phase 4 · completed
NCT04133584 — The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05373030 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Provincial Center for Disease Control and Prevention
Last refreshed: 13 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05373030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing